Immunotherapy has emerged as one of the major options for cancer treatment in the past decade. With the successful application of immune checkpoint inhibitors and the introduction of immune regulatory ...

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: ...

MaxCyte, Inc. is rated a "Buy" due to significant upside potential despite recent share price declines. Find out why.

MaxCyte (NASDAQ:MXCT – Free Report) had its price objective cut by Stifel Nicolaus from $11.00 to $9.00 in a report released on Wednesday morning,Benzinga reports. They currently have a buy rating on ...